Cyclin D1 binding to the androgen receptor (AR) NH2-terminal domain inhibits activation function 2 association and
C J Burd1, C E Petre, H Moghadam
1Department of Cell Biology, University of Cincinnati College of Medicine, P.O. Box 670521, 3125 Eden Avenue, Cincinnati, Ohio 45267-0521, USA.
Abstract:
The androgen receptor (AR) is a member of the nuclear receptor superfamily, the activity of which is critical for the development and progression of prostate cancer. We and others have previously demonstrated that cyclin D1 is a potent corepressor of the AR. Although cyclin D1 is suspected to recruit histone deacetylases to the AR complex, previous studies have demonstrated that this activity alone is insufficient for cyclin D1 function. Here, we uncover a novel, secondary means of cyclin D1-mediated repression, through modulation of AR amino-carboxy terminal interactions. We show that cyclin D1 predominantly binds the N-terminal domain of the AR, dependent on the AR 23FxxLF27 motif. Through this motif, cyclin D1 abrogates the ability of the AR N-terminal domain to interact with the C terminus. Secondary amino-terminal domain sites capable of fostering interaction with the C terminus were refractory to cyclin D1 action, indicating that the ability of cyclin D1 to modulate AR amino-carboxy terminal interactions is specific to 23FxxLF27. Deletion of the N-terminal cyclin D1 binding site severely compromised AR activity (due to loss of FxxLF) but unmasked a repressor action through interaction with the AR C terminus. In summary, these data reveal novel, unexpected mechanisms of cyclin D1 activity and demonstrate that this function of cyclin D1 is critical for AR modulation.
Insights
Cyclin D1 represses prostate cancer
Area of Science:
- Molecular Biology
- Cancer Research
- Endocrinology
Background:
- The androgen receptor (AR) is crucial for prostate cancer progression.
- Cyclin D1 is a known corepressor of the AR.
- Previous understanding of cyclin D1's repressive function was incomplete.
Purpose of the Study:
- To investigate novel mechanisms of cyclin D1-mediated repression of the AR.
- To elucidate the specific interactions between cyclin D1 and the AR.
Main Methods:
- Investigated cyclin D1 binding to the AR N-terminal domain.
- Utilized AR mutant lacking the 23FxxLF27 motif.
- Assessed AR activity and interactions following cyclin D1 modulation.
Main Results:
- Cyclin D1 binds the AR N-terminal domain via the 23FxxLF27 motif.
- This binding disrupts AR amino-carboxy terminal interactions.
- Deletion of the binding site impairs AR activity and reveals C-terminal repression.
Conclusions:
- Cyclin D1 employs a novel mechanism to repress AR activity by modulating its terminal interactions.
- This specific interaction is critical for AR modulation in prostate cancer.
- Identified new therapeutic targets for prostate cancer treatment.
More Related Videos
05:48Cell Aggregation Assays to Evaluate the Binding of the Drosophila Notch with Trans-Ligands and its Inhibition by Cis-Ligands
Published on: January 2, 2018
09:07Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay
Published on: December 19, 2018
Related Concept Videos
Positive Regulator Molecules
Positive Regulator Molecules
Inhibition of Cdk Activity
Anaphase Promoting Complex
GPCRs Regulate Adenylyl Cylase Activity
Two...
Inhibition of CDK Activity
